United CEO Martine Rothblatt

With pipeline set­backs mount­ing, Unit­ed snares pri­or­i­ty vouch­er for in­haled for­mu­la­tion of PAH med Ty­va­so

De­spite a big lead in pul­monary ar­te­r­i­al hypterten­sion, Unit­ed Ther­a­peu­tics is un­der the gun as it looks to stave off com­peti­tors and build a suc­cess­ful ex­pan­sion over in on­col­o­gy. So far, those re­sults have been mixed. But now, Unit­ed is on the cusp of adding a new for­mu­la­tion to its suc­cess­ful Ty­va­so fran­chise that could spur growth.

For a cool price tag of $105 mil­lion, Unit­ed Ther­a­peu­tics has snared a pri­or­i­ty re­view vouch­er (PRV) for rare pe­di­atric dis­eases from Y-mAbs Ther­a­peu­tics that it in­tends to use to help take an in­haler ver­sion of its hy­per­ten­sion med Ty­va­so across the fin­ish line, the com­pa­ny said Mon­day. The vouch­er was orig­i­nal­ly in­tend­ed for Y-mAbs’ ap­pli­ca­tion for Danyelza in neu­rob­las­toma and wasn’t used for the FDA’s ap­proval in No­vem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.